Vor Biopharma Inc at Goldman Sachs Healthcare Conference Transcript
Yeah, sure. So Vor is a cell therapy company. We're a little bit different to other companies. We actually focus on engineering hematopoietic stem cells. So these are the cells that populate your blood system, live in the bone marrow that give rise to cancer.
Now, of course, bone marrow transplantation has been the standard of care for many years. Unfortunately, even with a transplant, a lot of patients with cancer still relapse very quickly. So the whole premise behind Vor is to create next-generation stem cell transplants that are resistant to targeted therapies, and we use genome engineering to do that. So by manipulating the genome of these stem cells that we're using as the next-gen transplant, we're hoping that we can we open up a whole universe of treatment opportunities for patients.
Questions & Answers
(technical difficulty) on Friday of you lead program (technical difficulty) or high risk (technical difficulty) maybe walk us through (technical
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
